The recently listed company’s investors get déjà vu with the first human data from a trial of the allogeneic cell therapy CB-010.
After a long wait, investors at last have early evidence that Nkarta’s Car-NK cells work – with a relatively clean safety profile to boot.
Evaluate Vantage's coverage of the Ash 2021 congress.
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.
Several cell therapy presentations will vie for attention at Ash, though today the spotlight falls on Autolus.
A low-key cancer discovery alliance sees Roche abandoning its earlier opposition to cell therapies.